$ANRO

Alto Neuroscience Inc. reports Q3 results Wednesday, with analysts expecting a loss of $0.82 per share. The company, which has no revenue, has seen EPS estimates decline 2.68% over 60 days. Despite losses, analysts rate it a Strong Buy with a $38.67 price target, implying 39% upside. Investors focus on cash runway and trial progress, particularly ALTO-207 for treatment-resistant depression, with key readouts expected in 2027.

HC Wainwright & Co. reiterated a Buy rating and $60 price target for Alto Neuroscience, implying a 173.5% upside from the Oct 16 close of $21.94. The firm cited strong clinical evidence and significant market potential for the company's psychiatric treatments.

Alto Neuroscience's President and CFO, Nicholas Conrad Smith, sold shares worth $3.57M under a 10b5-1 plan, at average prices of $26.58, $25.78, and $26.87. He now directly owns 24,060 shares, according to an SEC filing.

Smith Nicholas Conrad (PRESIDENT AND CFO) sold 134,886 shares of Alto Neuroscience, Inc. (ANRO) at an average of $26.45 ($25.78–$26.87, $3.57M total) across 3 trades over 2026-09-29 to 2026-09-30 under a Rule 10b5-1 trading plan.

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 26, 2026 (the “ Effective Date” ), the Board of Directors (the “ Board ”) of Alto Neuroscience, Inc. (the “ Compa

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoin

Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620328d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 13, 2026 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGRE

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Alto Neuroscience reported a net loss of $26.2 million for Q1 2026, an increase from $15.2 million in Q1 2025, but ended the quarter with $264.2 million in cash following a March PIPE financing. The company expects this funding to support operations through 2029, including a potential NDA submission for ALTO-207. Key business highlights include the initiation of a Phase 2b trial for ALTO-207, advancements with ALTO-101, and ongoing Phase 2b trials for ALTO-300 and ALTO-100 with projected topline readouts in 2027.